Literature DB >> 26140401

Preoperative opioid strength may not affect outcomes of anterior cervical procedures: a post hoc analysis of 2 prospective, randomized trials.

Michael P Kelly1, Paul A Anderson2, Rick C Sasso3, K Daniel Riew1.   

Abstract

OBJECT: The aim of this study is to evaluate the relationship between preoperative opioid strength and outcomes of anterior cervical decompressive surgery.
METHODS: A retrospective cohort of 1004 patients enrolled in 1 of 2 investigational device exemption studies comparing cervical total disc arthroplasty (TDA) and anterior cervical discectomy and fusion (ACDF) for single-level cervical disease causing radiculopathy or myelopathy was selected. At a preoperative visit, opioid use data, Neck Disability Index (NDI) scores, 36-Item Short-Form Health Survey (SF-36) scores, and numeric rating scale scores for neck and arm pain were collected. Patients were divided into strong (oxycodone/morphine/meperidine), weak (codeine/propoxyphene/hydrocodone), and opioid-naïve groups. Preoperative and postoperative (24 months) outcomes scores were compared within and between groups using the paired t-test and ANCOVA, respectively.
RESULTS: Patients were categorized as follows: 226 strong, 762 weak, and 16 opioid naïve. The strong and weak groups were similar with respect to age, sex, race, marital status, education level, Worker's Compensation status, litigation status, and alcohol use. At 24-month follow-up, no differences in change in arm or neck pain scores (arm: strong -52.3, weak -50.6, naïve -54.0, p = 0.244; neck: strong -52.7, weak -50.8, naïve -44.6, p = 0.355); NDI scores (strong -36.0, weak -33.3, naïve -32.3, p = 0.181); or SF-36 Physical Component Summary scores (strong: 14.1, weak 13.3, naïve 21.7, p = 0.317) were present. Using a 15-point improvement in NDI to determine success, the authors found no between-groups difference in success rates (strong 80.6%, weak 82.7%, naïve 73.3%, p = 0.134). No difference existed between treatment arms (TDA vs ACDF) for any outcome at any time point.
CONCLUSIONS: Preoperative opioid strength did not adversely affect outcomes in this analysis. Careful patient selection can yield good results in this patient population.

Entities:  

Keywords:  ACDF = anterior cervical discectomy and fusion; IDE = investigational device exemption; MCS = Mental Component Summary; NDI = Neck Disability Index; PCS = Physical Component Summary; SF-36 = 36-Item Short-Form Health Survey; TDA = total disc arthroplasty; cervical arthroplasty; cervical fusion; narcotic; opioid; pain

Mesh:

Substances:

Year:  2015        PMID: 26140401      PMCID: PMC4701382          DOI: 10.3171/2015.1.SPINE14985

Source DB:  PubMed          Journal:  J Neurosurg Spine        ISSN: 1547-5646


  15 in total

Review 1.  Analgesic pharmacology: I. Neurophysiology.

Authors:  William J Phillips; Bradford L Currier
Journal:  J Am Acad Orthop Surg       Date:  2004 Jul-Aug       Impact factor: 3.020

Review 2.  A comprehensive review of opioid-induced hyperalgesia.

Authors:  Marion Lee; Sanford M Silverman; Hans Hansen; Vikram B Patel; Laxmaiah Manchikanti
Journal:  Pain Physician       Date:  2011 Mar-Apr       Impact factor: 4.965

3.  Reduction in narcotic use after primary total knee arthroplasty and association with patient pain relief and satisfaction.

Authors:  Patricia D Franklin; John A Karbassi; Wenjun Li; Wenyun Yang; David C Ayers
Journal:  J Arthroplasty       Date:  2010-06-26       Impact factor: 4.757

4.  Chronic opioid use prior to total knee arthroplasty.

Authors:  Michael G Zywiel; D Alex Stroh; Seung Yong Lee; Peter M Bonutti; Michael A Mont
Journal:  J Bone Joint Surg Am       Date:  2011-11-02       Impact factor: 5.284

5.  Predictors of outcome after anterior cervical discectomy and fusion: a multivariate analysis.

Authors:  Paul A Anderson; Brian R Subach; K Daniel Riew
Journal:  Spine (Phila Pa 1976)       Date:  2009-01-15       Impact factor: 3.468

6.  Cervical disc arthroplasty compared with arthrodesis for the treatment of myelopathy.

Authors:  K Daniel Riew; Jacob M Buchowski; Rick Sasso; Thomas Zdeblick; Newton H Metcalf; Paul A Anderson
Journal:  J Bone Joint Surg Am       Date:  2008-11       Impact factor: 5.284

7.  Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000.

Authors:  Margaret A Caudill-Slosberg; Lisa M Schwartz; Steven Woloshin
Journal:  Pain       Date:  2004-06       Impact factor: 6.961

8.  Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease.

Authors:  Daniel Murrey; Michael Janssen; Rick Delamarter; Jeffrey Goldstein; Jack Zigler; Bobby Tay; Bruce Darden
Journal:  Spine J       Date:  2008-09-06       Impact factor: 4.166

9.  Preoperative narcotic use as a predictor of clinical outcome: results following anterior cervical arthrodesis.

Authors:  J Todd R Lawrence; Nickolas London; Henry H Bohlman; Kingsley R Chin
Journal:  Spine (Phila Pa 1976)       Date:  2008-09-01       Impact factor: 3.468

10.  Higher opioid doses predict poorer functional outcome in patients with chronic disabling occupational musculoskeletal disorders.

Authors:  Cindy L Kidner; Tom G Mayer; Robert J Gatchel
Journal:  J Bone Joint Surg Am       Date:  2009-04       Impact factor: 5.284

View more
  3 in total

1.  Preoperative opioids before adult spinal deformity surgery associated with increased reoperations and high rates of chronic postoperative opioid use at 3-year follow-up.

Authors:  Andre M Samuel; Kyle W Morse; Yuri A Pompeu; Avani S Vaishnav; Catherine Himo Gang; Han Jo Kim; Sheeraz A Qureshi
Journal:  Spine Deform       Date:  2022-01-22

Review 2.  Rationale for and approach to preoperative opioid weaning: a preoperative optimization protocol.

Authors:  Heath McAnally
Journal:  Perioper Med (Lond)       Date:  2017-11-22

3.  Tapentadol extended release for the management of chronic neck pain.

Authors:  Domenico Billeci; Flaminia Coluzzi
Journal:  J Pain Res       Date:  2017-03-02       Impact factor: 3.133

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.